Tags

Type your tag names separated by a space and hit enter

Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia.
Clin Investig 1993; 71(4):314-8CI

Abstract

The effects of two moderate doses of long-chain n-3 fatty acids (3.0 and 4.5 g EPA+DHA per day for 4 weeks each) on serum lipids and lipoproteins of patients with familial combined hyperlipidemia (FCH) were studied in a double-blind, placebo-controlled clinical trial. In nine patients with FCH n-3 fatty acids led to a statistically significant, dose-dependent fall in very low density lipoprotein (VLDL) triglycerides (3 g/day: -42%, 4.5 g/day: -55%) VLDL cholesterol (3 g/day: -41%, 4.5 g/day: -47%), and VLDL apolipoprotein (apo) B-100 (3 g/day: -40%, 4.5 g/day: -56%). No overall change in low-density lipoprotein (LDL) cholesterol was found, as confirmed statistically. However, when analyzing the data of single patients LDL cholesterol and LDL apo B did not change in five patients but increased dose dependently (from pretreatment 4.80 +/- 0.93 mmol/l to 5.70 +/- 0.93 mmol/l LDL cholesterol after 4.5 g/day) in four. LDL and VLDL composition as indicated by cholesterol/apo B-100 and triglyceride/apo B-100 ratios did not change significantly. High-density lipoprotein (HDL) cholesterol was unchanged; the HDL cholesterol/apo A-I+apo A-II ratio increased by 19% (P < 0.05) during fish oil treatment. We conclude that in FCH moderate doses of long-chain n-3 fatty acids are highly effective in lowering pathological VLDL triglycerides, VLDL cholesterol, and VLDL apo B. LDL cholesterol must, however, be monitored during treatment as it may rise substantially in some although not in all patients with this disease.

Authors+Show Affiliations

Medizinische Poliklinik, Universität München.No affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

8471818

Citation

Tatò, F, et al. "Effects of Fish Oil Concentrate On Lipoproteins and Apolipoproteins in Familial Combined Hyperlipidemia." The Clinical Investigator, vol. 71, no. 4, 1993, pp. 314-8.
Tatò F, Keller C, Wolfram G. Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia. Clin Investig. 1993;71(4):314-8.
Tatò, F., Keller, C., & Wolfram, G. (1993). Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia. The Clinical Investigator, 71(4), pp. 314-8.
Tatò F, Keller C, Wolfram G. Effects of Fish Oil Concentrate On Lipoproteins and Apolipoproteins in Familial Combined Hyperlipidemia. Clin Investig. 1993;71(4):314-8. PubMed PMID: 8471818.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of fish oil concentrate on lipoproteins and apolipoproteins in familial combined hyperlipidemia. AU - Tatò,F, AU - Keller,C, AU - Wolfram,G, PY - 1993/4/1/pubmed PY - 1993/4/1/medline PY - 1993/4/1/entrez SP - 314 EP - 8 JF - The Clinical investigator JO - Clin Investig VL - 71 IS - 4 N2 - The effects of two moderate doses of long-chain n-3 fatty acids (3.0 and 4.5 g EPA+DHA per day for 4 weeks each) on serum lipids and lipoproteins of patients with familial combined hyperlipidemia (FCH) were studied in a double-blind, placebo-controlled clinical trial. In nine patients with FCH n-3 fatty acids led to a statistically significant, dose-dependent fall in very low density lipoprotein (VLDL) triglycerides (3 g/day: -42%, 4.5 g/day: -55%) VLDL cholesterol (3 g/day: -41%, 4.5 g/day: -47%), and VLDL apolipoprotein (apo) B-100 (3 g/day: -40%, 4.5 g/day: -56%). No overall change in low-density lipoprotein (LDL) cholesterol was found, as confirmed statistically. However, when analyzing the data of single patients LDL cholesterol and LDL apo B did not change in five patients but increased dose dependently (from pretreatment 4.80 +/- 0.93 mmol/l to 5.70 +/- 0.93 mmol/l LDL cholesterol after 4.5 g/day) in four. LDL and VLDL composition as indicated by cholesterol/apo B-100 and triglyceride/apo B-100 ratios did not change significantly. High-density lipoprotein (HDL) cholesterol was unchanged; the HDL cholesterol/apo A-I+apo A-II ratio increased by 19% (P < 0.05) during fish oil treatment. We conclude that in FCH moderate doses of long-chain n-3 fatty acids are highly effective in lowering pathological VLDL triglycerides, VLDL cholesterol, and VLDL apo B. LDL cholesterol must, however, be monitored during treatment as it may rise substantially in some although not in all patients with this disease. SN - 0941-0198 UR - https://www.unboundmedicine.com/medline/citation/8471818/Effects_of_fish_oil_concentrate_on_lipoproteins_and_apolipoproteins_in_familial_combined_hyperlipidemia_ L2 - http://www.diseaseinfosearch.org/result/8593 DB - PRIME DP - Unbound Medicine ER -